Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG7 | O95352 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293016 | 1.00 | ATG7 (0.47) | ATG7POLBENPP1P2RY1RXFP1 | |
| SCHEMBL21317437 | 0.89 | POLB (0.47) | POLBENPP1P2RY1 | |
| SCHEMBL30197148 | 0.89 | POLB (0.47) | POLBENPP1P2RY1 | |
| SCHEMBL7215063 | 0.89 | POLB (0.47) | POLBENPP1P2RY1 | |
| SCHEMBL11986893 | 0.89 | POLB (0.47) | POLBENPP1P2RY1 | |
| SCHEMBL19302887 | 0.87 | ATG7 (0.49) | ATG7POLBENPP1P2RY1RXFP1 | |
| SCHEMBL9548819 | 0.86 | ADA (0.53) | POLBENPP1P2RY1RXFP1 | |
| SCHEMBL9548829 | 0.86 | ADA (0.53) | POLBENPP1P2RY1RXFP1 | |
| SCHEMBL2289562 | 0.84 | RXFP1 (0.47) | RXFP1 | |
| SCHEMBL2289557 | 0.84 | RXFP1 (0.47) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019006467-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | WO | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | ATG7 2377/4885POLB 933/4885ENPP1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.